Amneal obtains non-infringement finding in Sensipar case
01-08-2018
tomloel / iStockphoto.com
A district court has granted a stipulated order to the US Food and Drug Administration (FDA) and Amgen, after they jointly asked the court to end a case centring on paediatric exclusivity for Sensipar (cinacalcet).
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Amgen, FDA, Sensipar, paediatric exclusivity, patent, TRO,
